Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.02.2013 | review

Chronic myelomonocytic leukaemia: diagnosis and therapeutic implications

verfasst von: Sonja Burgstaller, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Chronic myelomonocytic leukaemia (CMML) is a clonal disorder of the haematopoietic stem cell characterised by the presence of an absolute monocytosis in peripheral blood. The disease carries myelodysplastic and myeloproliferative features. This dilemma was sought to be overcome by the World Health Organization (WHO) in 2001, when CMML was classified within a new category of myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN). The identification of molecular markers in patients with CMML has dramatically increased over the past couple of years. However, the impact on prognosis and therapeutic interventions needs to be defined. Testing of new agents in the setting of CMML proves to be difficult due to limited number of patients. This review has a focus on current diagnosis including new molecular data and treatment of CMML.
Vorheriger Artikel Selected breast cancer highlights from the ASCO 2012
Nächster Artikel Management of immunosuppression in the treatment of chronic lymphocytic leukemia
Literatur
1.
Vardiman JW, Pierre R, Bain B, Bennett JM, Imbert M, Brunning RD, et al. WHO histological classification of myelodysplastic/myeloproliferative diseases. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours: tumours of the haematopoietic and lympoid tissues. Lyon: International Agency for Research on Cancer (IARC) Press; 2001. pp. 47–59.
2.
Kern W, Bacher U, Haferlach C, Schnittger S, Haferlach T. Acute monoblastic/monocytic leukemia and chronic myelomonocytic leukemia share common immunophenotypic features but differ in the extent of aberrantly expressed antigens and amount of granulocytic cells. Leuk Lymphoma. 2011;52:92–100.PubMedCrossRef
3.
Subira D, Font P, Villalon L, Serrano C, Askari E, Gongora E, et al. Immonophenotype in chronic myelomonocytic leukemia: is it closer to myelodysplastic syndromes or to myeloproliferative disorders? Transl Res. 2008;151:240–5.PubMedCrossRef
4.
Gorczyca W. Flow cytometry immunophenotypic characteristics of monocytic population in acute monocytic leukaemia (AML-M5), acute myelomonocytic leukaemia (AML-M4), and chronic myelomonocytic leukaemia (CMML). Methods Cell Biol. 2004;75:665–7.PubMedCrossRef
5.
Xu Y, McKenna RW, Karandikar NJ, Pildain AJ, Kroft SH. Flow cytometric analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukemia from reactive monocytosis. Am J Clin Pathol. 2005;124:799–806.PubMedCrossRef
6.
Vardiman JW, Imbert M, Pierre R, Brunning RD, Bain B, Flandrin G, et al. Chronic myelomonocytic leukaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumors: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. pp. 49–52.
7.
Orazi A, Chiu R, O’Malley DP, Czader M, Allen SL, An C, Vance GH. Chronic myelomonocytic leukemia: the role of bone marrow biopsy immunohistolog. Mod Pathol. 2006;19:1536–45.PubMedCrossRef
8.
Germing U, Gattermann N, Minning H, Heyll A, Aul C. Problems in the classification of CMML-dysplastic versus proliferative type. Leuk Res. 1998;22:871–8.PubMedCrossRef
9.
Fenaux P, Beuscart R, Lai JL, Jouet JP, Bauters F. Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. J Clin Oncol. 1988;6:1417–24.PubMed
10.
Storniolo AM, Moloney WC, Rosenthal DS, Cox C, Bennett JM. Chronic myelomonocytic leukemia. Leukemia. 1990;4:766–70.PubMed
11.
McClure RF, Dewald GW, Hoyer JK, Hanson CA. Isolated isochromosome 17q: a distinct type of mixed myeloproliferative disorder/myelodysplastic syndrome with an aggressive clinical course. Br J Haematol. 1999;106:445–54.PubMedCrossRef
12.
Burgstaller S, Reiter A, Cross NCP. BCR-ABL negative chronic myeloid leukemia. Curr Hem Malignancy Rep. 2007;2:75–82.CrossRef
13.
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.PubMedCrossRef
14.
Kosmider O, Gelsi-Bayer V, Ciudad M, Racoeur C, Jooste V, Vey N, et al. TET2 gene mutationis a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica. 2009;94:1676–81.PubMedCrossRef
15.
Kohlmann A, Grossmann V, Klein H, Schindela S, Weiss T, Kazak B, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol. 2010;28:3858–65.PubMedCrossRef
16.
Dunbar AJ, Gondek LP, O’Keefe CL, Makishima H, Rataul MS, Szpurka H, et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res. 2008;68:10349–57.
17.
Ricci C, Fermo E, Corti S, Molteni M, Faricciotti A, Cortelezzi A, et al. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant. Clin Cancer Res. 2010;16:2246–56.PubMedCrossRef
18.
Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zahng L, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162–8.PubMedCrossRef
19.
Pich A, Riera L, Sismondi F, Godio L, Davico Bonino L, Marmont F, Francia di Celle P. JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia. J Clin Pathol. 2009;62:798–801.PubMedCrossRef
20.
Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood. 2009;113:6182–92.PubMedCrossRef
21.
Gelsi-Boyer V, Trouplin V, Adelaide J, Aceto N, Remy V, Pinson S, et al. Genome profiling of chronic myelomonoytic leukemia: frequent alterations of RAS and RUNX1 genes. BMC Cancer. 2008;8:299.
22.
Kuo MC, Liang DC, Huang CF, Shih YS, Wu JH, Lin TL, Shih LY. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. Leukemia. 2009;23:1426–31.PubMedCrossRef
23.
Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, Carbuccia N, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndrome and chronic myelomonocytic leukaemia. Br J Haematol. 2009;145:788–800.PubMedCrossRef
24.
Germing U, Kündgen A, Gattermann N. Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma. 2004;45:1311–8.PubMedCrossRef
25.
Molica S, Iannaccuro P, Albeti A. Chronic myelomonocytic leukemia: a test of a proposed staging system. Am J Haematol. 1990;35:129–30.CrossRef
26.
Worsley A, Oscier DG, Stevens J, Darlow S, Figes A, Mufti GJ, Hamblin TJ. Prognostic features of chronic myelomonocytic leukemia: a modified Bournemouth score gives the best prediction of survival. Br J Haematol. 1988;68:17–21.PubMedCrossRef
27.
Aul C, Ganttermann N, Neyll A, Germing U, Gerigs G, Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia. 1992;6:52–9.PubMed
28.
Gonzales-Medina I, Bueno J, Torrequebrada A, Lopez A, Vallespi T, Massague I. Two groups of chronic myelomonocytic leukemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center. Leuk Res. 2002;26:821–4.CrossRef
29.
Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002; 99: 840–9.PubMedCrossRef
30.
Beran M, Wen S, Shen Y, Onida F, Jelinek J, Cortes J, et al. Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognositc Scoring System. Leuk Lymphoma. 2007;48:1150–60.PubMedCrossRef
31.
Wattel E, Guerci A, Hecquet B, Economopoulos T, Copplestone A, Mahe B, et al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Blood. 1996;88:2480–7.PubMed
32.
Beran M, Estey E, O’Brien S, Giles FJ, Koller CA, Kornblau S, et al. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk lymphoma. 1998;31:521–31.PubMed
33.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–32.
34.
Wong E, Seymour JF, Kenealy M, Westerman D, Herbert K, Dickinson M. Treatment of chronic myelomonocytic leukemia with azacitidine. Leuk Lymphoma. 2012. Epub ahead of print.
35.
Feldman E, Cortes J, DeAngelo DJ, Holyoake T, Simonsson B, O’Brien SG, et al. On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia. 2008;22:1707–11.PubMedCrossRef
36.
Sliitonen T, Timonen T, Juvonen E, Terävä V, Kutila A, Honkanen T, et al. Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes. Haematologica. 2007;92:1119–22.CrossRef
37.
Eissa H, Gooley TA, Sorror ML, Nguyen F, Scott BL, Doney K, et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. Biol Blood Marrow Transpl. 2010. doi:10.1016/j.bbmt.2010.09.018.
Metadaten
Titel
Chronic myelomonocytic leukaemia: diagnosis and therapeutic implications
verfasst von
Sonja Burgstaller, MD
Publikationsdatum
01.02.2013
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0064-6

Weitere Artikel der Ausgabe 1/2013

Management of immunosuppression in the treatment of chronic lymphocytic leukemia

  • short review

Development of treatment and clinical results in childhood acute myeloid leukemia in the Slovak Republic

  • short review

Development of treatment and clinical results in childhood acute myeloid leukemias in Hungary

  • short review

Future of stereotactic intervention in lung cancer

  • editorial

Maintenance therapy in NSCLC

  • short review

Development of treatment and clinical results in childhood acute myeloid leukemia in the Czech Republic

  • short review